ABC1 Consensus Conference – a German Perspective

Abstract

A group of German breast cancer experts (medical oncologists and gynaecologists) reviewed and commented on the results of the first international ‘Advanced Breast Cancer First Consensus Conference’ (ABC1) for the diagnosis and treatment of advanced breast cancer. The ABC1 Conference is an initiative of the European School of Oncology (ESO) Metastatic Breast Cancer Task Force in cooperation with the EBCC (European Breast Cancer Conference), ESMO (European Society of Medical Oncology) and the American JNCI (Journal of the National Cancer Institute). The main focus of the ABC1 Conference was metastatic breast cancer (stage IV). The ABC1 consensus is based on the vote of 33 breast cancer experts from different countries and has been specified as a guideline for therapeutic practice by the German expert group. It is the objective of the ABC1 consensus as well as of the German comments to provide an internationally standardized and evidence-based foundation for qualified decision-making in the treatment of metastatic breast cancer.

Barrier protective use of skin care to prevent chemotherapy-induced cutaneous symptoms and to maintain quality of life in patients with breast cancer

“… 1 With approximately 75,000 new cases each year, breast cancer is a common tumor in Germany and by far the most frequent malignant tumor in women. 2 Based on guidelines, therapeutic regimens are chosen depending on clinical grading, hormone receptor state, lymph node involving, and the patient’s age. For intermediate and high-risk conditions, this almost always involves adjuvant systemic chemotherapy.…”

Surgery of the primary tumor improves survival in women with stage IV breast cancer in Southwest China

“…[ 13 ] The ABC guidelines have been always concerned about the effect of resection of the primary tumor for stage IV breast cancer. [ 7 , 8 , 25 ] According to the third international consensus, the breast tumor removal can be considered on an individual basis for selected patients, particularly to improve quality of life. And the approach is currently being investigated further in prospective clinical studies.…”

Barrier protective use of skin care to prevent chemotherapy-induced cutaneous symptoms and to maintain quality of life in patients with breast cancer

“…1 With approximately 75,000 new cases each year, breast cancer is a common tumor in Germany and by far the most frequent malignant tumor in women. 2 Based on guidelines, therapeutic regimens are chosen depending on clinical grading, hormone receptor state, lymph node involving, and the patient's age. For intermediate and high-risk conditions, this almost always involves adjuvant systemic chemotherapy.…”